Advertisement

Interpreting Clinical Studies of Putative Therapeutics for Alzheimer's Disease: The Case of Statins and NSAIDs

  • Benjamin Wolozin

Epidemiological studies have identified numerous existing medications that appear to be associated with a reduced incidence or progression of Alzheimer’s disease. The literature surrounding these studies is confusing because of conflicting data. Retrospective epidemiological studies of both statins and nonsteroidal anti-inflammatory drugs (NSAIDs) show an association between medication use and a reduced incidence or progression of AD (Breitner et al., 1994; Jick, Zornberg, Jick, Seshadri, & Drachman, 2000; Wolozin, Kellman, Ruosseau, Celesia, & Siegel, 2000).

Keywords

Alzheimer Disease Statin Treatment Health Care Database Health Care Record Retrospective Epidemiological Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., et al. (2003). Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. The Journal of the American Medical Association, 289, 2819–2826.CrossRefGoogle Scholar
  2. Bi, X., Baudry, M., Liu, J., Yao, Y., Fu, L., Brucher, F., et al. (2004). Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia. The Journal of Biological Chemistry, 279, 48238–48245.CrossRefPubMedGoogle Scholar
  3. Breitner, J. C., Gau, B. A., Welsh, K. A., Plassman, B. L., McDonald, W. M., Helms, M. J., et al. (1994). Inverse association of anti-inflammatory treatments and Alzheimer' disease: Initial results of a co-twin control study. Neurology, 44, 227–232.PubMedGoogle Scholar
  4. Breitner, J. C., Welsh, K. A., Helms, M. J., Gaskell, P. C., Gau, B. A., Roses, A. D., et al. (1995). Delayed onset of Alzheimer' disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiology of Aging, 16, 523–530.CrossRefPubMedGoogle Scholar
  5. Cole, S. L., Grudzien, A., Manhart, I. O., Kelly, B. L., Oakley, H., & Vassar, R. (2005). Statins cause intracellular accumulation of APP, beta-secretase cleaved fragments, and Abeta via an isoprenoid-dependent mechanism. The Journal of Biological Chemistry, 280, 18755–18770.CrossRefPubMedGoogle Scholar
  6. Cordle, A., Koenigsknecht-Talboo, J., Wilkinson, B., Limpert, A., & Landreth, G. (2005). Mechanisms of statin-mediated inhibition of small G-protein function. The Journal of Biological Chemistry, 280, 34202–34209.CrossRefPubMedGoogle Scholar
  7. Cordle, A., & Landreth, G. (2005). 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. The Journal of Neuroscience, 25, 299–307.CrossRefPubMedGoogle Scholar
  8. Etminan, M., Gill, S., & Samii, A. (2003). Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer' disease: Systematic review and meta-analysis of observational studies. British Medical Journal, 327, 128.CrossRefPubMedGoogle Scholar
  9. Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lutjohann, D., Keller, P., et al. (2001). Simvastatin strongly reduces Alzheimer' disease Ab42 and Ab40 levels in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 98, 5856–5861.CrossRefPubMedGoogle Scholar
  10. Heart Protection Study Collaborative Group. (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: A randomised placebo-controlled trial. Lancet, 360, 7–22.CrossRefGoogle Scholar
  11. Hernandez-Perera, O., Perez-Sala, D., Navarro-Antolin, J., Sanchez-Pascuala, R., Hernandez, G., Diaz, C., et al. (1998). Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. The Journal of Clinical Investigation, 101, 2711–2719.CrossRefPubMedGoogle Scholar
  12. Hoglund, K., Wiklund, O., Vanderstichele, H., Eikenberg, O., Vanmechelen, E., & Blennow, K. (2004). Plasma levels of beta-amyloid(1–40), beta-amyloid(1–42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Archives of Neurology, 61, 333–337.CrossRefPubMedGoogle Scholar
  13. Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S., & Drachman, D. A. (2000). Statins and the risk of dementia. Lancet, 356, 1627–1631.CrossRefPubMedGoogle Scholar
  14. Johnson, T. E., Zhang, X., Bleicher, K. B., Dysart, G., Loughlin, A. F., Schaefer, W. H., et al. (2004). Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicology and Applied Pharmacology, 200, 237–250.CrossRefPubMedGoogle Scholar
  15. Johnson-Anuna, L. N., Eckert, G. P., Keller, J. H., Igbavboa, U., Franke, C., Fechner, T., et al. (2005). Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. The Journal of Pharmacology and Experimental Therapeutics, 312, 786–793.CrossRefPubMedGoogle Scholar
  16. Li, G., Higdon, R., Kukull, W. A., Peskind, E., Van Valen Moore, K., Tsuang, D., et al. (2004). Statin therapy and risk of dementia in the elderly: A community-based prospective cohort study. Neurology, 63, 1624–1628.PubMedGoogle Scholar
  17. Lu, D., Goussev, A., Chen, J., Pannu, P., Li, Y., Mahmood, A., et al. (2004). Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury. Journal of Neurotrauma, 21, 21–32.CrossRefPubMedGoogle Scholar
  18. Lutjohann, D., Stroick, M., Bertsch, T., Kuhl, S., Lindenthal, B., Thelen, K., et al. (2004). High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids, 69, 431–438.CrossRefPubMedGoogle Scholar
  19. Marz, W., & Koenig, W. (2003). HMG-CoA reductase inhibition: Anti-inflammatory effects beyond lipid lowering? Journal of Cardiovascular Risk, 10, 169–179.CrossRefPubMedGoogle Scholar
  20. Masse, I., Bordet, R., Deplanque, D., Al Khedr, A., Richard, F., Libersa, C., et al. (2005). Lipid lowering agents are associated with a slower cognitive decline in Alzheimer' disease. Journal of Neurology, Neurosurgery, and Psychiatry, 76, 1624–1629.CrossRefPubMedGoogle Scholar
  21. McGeer, P. L., & McGeer, E. G. (1996). Anti-inflammatory drugs in the fight against Alzheimer' disease. Annals of the New York Academy of Sciences, 777, 213–220.CrossRefPubMedGoogle Scholar
  22. Park, I. H., Hwang, E. M., Hong, H. S., Boo, J. H., Oh, S. S., Lee, J., et al. (2003). Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. Neurobiology of Aging, 24, 637–643.CrossRefPubMedGoogle Scholar
  23. Pedrini, S., Carter, T. L., Prendergast, G., Petanceska, S., Ehrlich, M. E., & Gandy, S. (2005). Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLos Medicine 2, e18.CrossRefPubMedGoogle Scholar
  24. Petanceska, S. S., DeRosa, S., Olm, V., Diaz, N., Sharma, A., Thomas-Bryant, T., et al. (2002). Statin therapy for Alzheimer' disease: Will it work? Journal of Molecular Neuroscience, 19, 155–161.CrossRefPubMedGoogle Scholar
  25. Refolo, L. M., Pappolla, M. A., LaFrancois, J., Malester, B., Schmidt, S. D., Thomas-Bryant, T., et al. (2001). A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer' disease. Neurobiology of Disease, 8, 890–899.CrossRefPubMedGoogle Scholar
  26. Rejnmark, L., Buus, N. H., Vestergaard, P., Andreasen, F., Larsen, M. L., & Mosekilde, L. (2002). Statins decrease bone turnover in postmenopausal women: A cross-sectional study. European Journal of Clinical Investigation, 32, 581–589.CrossRefPubMedGoogle Scholar
  27. Rockwood, K., Kirkland, S., Hogan, D. B., MacKnight, C., Merry, H., Verreault, R., et al. (2002). Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Archives of Neurology, 59, 223–227.CrossRefPubMedGoogle Scholar
  28. Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszniak, A. W., et al. (1993). Clinical trial of indomethacin in Alzheimer' disease. Neurology, 43, 1609–1611.PubMedGoogle Scholar
  29. Scharf, S., Mander, A., Ugoni, A., Vajda, F., & Christophidis, N. (1999). A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer' disease. Neurology, 53, 197–201.PubMedGoogle Scholar
  30. Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., et al. (2002). Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet, 360, 1623–1630.CrossRefPubMedGoogle Scholar
  31. Simons, M., Schwarzler, F., Lutjohann, D., Von Bergmann, K., Beyreuther, K., Dichgans, J., et al. (2002). Treatment with simvastatin in normocholesterolemic patients with Alzheimer' disease: A 26-week randomized, placebo-controlled, double- blind trial. Annals of Neurology, 52, 346–350.CrossRefPubMedGoogle Scholar
  32. Sjogren, M., Gustafsson, K., Syversen, S., Olsson, A., Edman, A., Davidsson, P., et al. (2003). Treatment with simvastatin in patients with Alzheimer' disease lowers both alpha- and beta-cleaved amyloid precursor protein. Dementia and Geriatric Cognitive Disorders, 16, 25–30.CrossRefPubMedGoogle Scholar
  33. Sparks, D. L., Sabbagh, M. N., Connor, D. J., Lopez, J., Launer, L. J., Browne, P., et al. (2005). Atorvastatin for the treatment of mild to moderate Alzheimer disease: Preliminary results. Archives of Neurology, 62, 753–757.CrossRefPubMedGoogle Scholar
  34. Vega, G. L., Weiner, M. F., Lipton, A. M., Von Bergmann, K., Lutjohann, D., Moore, C., et al. (2003). Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Archives of Neurology, 60, 510–515.CrossRefPubMedGoogle Scholar
  35. Wagstaff, L. R., Mitton, M. W., Arvik, B. M., & Doraiswamy, P. M. (2003). Statin-associated memory loss: Analysis of 60 case reports and review of the literature. Pharmacotherapy, 23, 871–880.CrossRefPubMedGoogle Scholar
  36. Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., et al. (2001). A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature, 414, 212–216.CrossRefPubMedGoogle Scholar
  37. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G., & Siegel, G. (2000). Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Archives of Neurology, 57, 1439–1443.CrossRefPubMedGoogle Scholar
  38. Wolozin, B., Mange, J., Bryant, R., Cordy, J., Green, R., & McKee, A. (2006). Cholesterol, Alzheimer' disease and statins: Re-assessing the relationship between cholesterol, statins and Alzheimer' disease. Acta Neurologica Scandanavia, 185, 63–70.CrossRefGoogle Scholar
  39. Yaffe, K., Barrett-Connor, E., Lin, F., & Grady, D. (2002). Serum lipoprotein levels, statin use, and cognitive function in older women. Archives of Neurology, 59, 378–384.CrossRefPubMedGoogle Scholar
  40. Zacco, A., Togo, J., Spence, K., Ellis, A., Lloyd, D., Furlong, S., et al. (2003). 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. The Journal of Neuroscience, 23, 11104–11111.PubMedGoogle Scholar
  41. Zandi, P., Sparks, L., Khachaturian, A., Tschanz, J., Norton, M., Steinberg, M., et al. (2004). Do statins reduce risk of incident dementia and AD? The cache county study. Archives of General Psychiatry, 62, 217–224.CrossRefGoogle Scholar
  42. Zhang, F. L., & Casey, P. J. (1996). Protein prenylation: Molecular mechanisms and functional consequences. Annual Review of Biochemistry, 65, 241–269.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Benjamin Wolozin
    • 1
  1. 1.Department of PharmacologyBoston University School of MedicineBostonUSA

Personalised recommendations